The collaboration aims to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Ache, for a range of women’s health indications, starting with polycystic ovary syndrome (PCOS).
Under the terms of the agreement, MSRD and Aché will collaborate to advance Aché’s novel compound ACH000029 through phase 1b clinical trials with the opportunity to expand the collaboration after those studies.
Nemera's multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug that is used to treat moderately severe pain and inflammation, usually after surgery.